Home › Funds › Velan Capital Investment Management LP › ANTX
Velan Capital Investment Management LP position in ANTX
AN2 THERAPEUTICS INC · Health Care
Velan Capital Investment Management LP reported holding 40,000 shares of ANTX (AN2 THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$213K, representing 0.20% of its reported portfolio and ranking #31 among its reported holdings. Velan Capital Investment Management LP has disclosed ANTX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Velan Capital Investment Management LP's ANTX position evolved
Velan Capital Investment Management LP first disclosed a stake in ANTX in Q2 2026 at 40,000 shares (US$194K). The position peaked in Q3 2026 at 40,000 shares, worth US$213K. Across 2 filings, Velan Capital Investment Management LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 40,000 shares valued at US$213K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 40.00K | $193.60K | New |
| Q3 2026 | 40.00K | $212.80K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ANTX and 13F data
ANTX (AN2 THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in ANTX — the largest reported positions include Vivo Capital, LLC (US$16.8M), Commodore Capital LP (US$14.2M), Spruce Street Capital LP (US$9.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ANTX
- Vivo Capital, LLC 3.15M sh · $16.78M · Q3 2026
- Commodore Capital LP 2.93M sh · $14.20M · Q2 2026
- Spruce Street Capital LP 1.75M sh · $9.32M · Q3 2026
- Almitas Capital LLC 1.47M sh · $7.11M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 1.30M sh · $6.92M · Q3 2026
- Boxer Capital Management, LLC 749.03K sh · $3.63M · Q2 2026
- Tetragon Partners GP Ltd 603.42K sh · $3.21M · Q3 2026
- Sio Capital Management, LLC 548.10K sh · $2.92M · Q3 2026
- Ally Bridge Group (NY) LLC 526.32K sh · $2.55M · Q2 2026
- Aldebaran Capital, LLC 367.71K sh · $1.96M · Q3 2026
- Prosight Management, LP 350.88K sh · $1.87M · Q3 2026
- Stonepine Capital Management, LLC 350.88K sh · $1.87M · Q3 2026
More on Velan Capital Investment Management LP
FAQ
How long has Velan Capital Investment Management LP held ANTX?
Velan Capital Investment Management LP has disclosed ANTX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Velan Capital Investment Management LP's current position in ANTX?
As of Q3 2026, Velan Capital Investment Management LP holds 40.00K shares of ANTX (AN2 THERAPEUTICS INC), valued at $212.80K, representing 0.20% of its reported portfolio and ranking #31.
Has Velan Capital Investment Management LP been buying or selling ANTX?
In the latest 13F filing (Q3 2026), Velan Capital Investment Management LP held unchanged its position in ANTX. The position peaked in Q3 2026 at 40.00K shares.
Which other funds hold ANTX?
Other major institutional holders of ANTX include Vivo Capital, LLC, Commodore Capital LP, Spruce Street Capital LP, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.